Health knowledge and news provided by doctors.

Ads by Google

Ovarian Cancer

Ovarian cancer is a challenging disease, from recognizing its symptoms to prevention, diagnosis, and treatment options. Emaxhealth reporters cover the latest research and advice from experts on all facets of ovarian cancer.

BSI-201 Demonstrates Significant Tumor Growth Inhibition In Ovarian Cancer Studies

BiPar Sciences announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug resistant xenograft models of ovarian cancer.


BioNumerik Commences Ovarian Cancer Trial On Karenitecin

BioNumerik Pharmaceuticals initiates global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Based on prior studies, BioNumerik believes Karenitecin has the potential for fewer side-effects, better efficacy, and less susceptibility to drug resistance mechanisms compared to the currently marketed camptothecin drugs.


Biomarkers Help Detect Early-Stage Ovarian Cancer

Vermillion presented data demonstrating that several of Vermillion's ovarian cancer protein biomarkers could be used to detect early-stage ovarian cancer and to predict survival. These poster presentations were made at the 15th International Meeting of the European Society of Gynecological Oncology (ESGO) in Berlin, Germany.